Search 

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.

Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.

Medherant develops transdermal drug patch products based on our next-generation TEPI-Patch® transdermal drug technology. Our lead product, a testosterone patch for women, is currently in the clinic.

Key advantages of the TEPI Patch® technology are high adhesion (up to 7 days) without irritation and with no pain on removal; patches are thin, flexible and comfortable; and they are water resistant and leave no residues or dirty marks. In addition, no solvents are required for the manufacturing processes.

As well as developing our own products, Medherant is working with a major multinational company to develop a multi-day patch for one of their drugs. We offer rapid feasibility studies to other companies interested in exploring the potential to develop transdermal formulations of their drugs of interest.

MediWales is the life science network and representative body for Wales.
An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.

MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally. 

Exhibiting at booth 50 with the UK delegation, the NIHR (National Institute for Health Research) funds, enables and delivers world-class health and care research that transforms people’s lives, advances science globally and benefits the UK economy.

The NIHR:

- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research

- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future

- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services

- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy

Nevrargenics Ltd is a UK-based neuroscience company specialising in the discovery and development of novel medicines for the treatment of neurodegenerative disease, such as Alzheimer’s, Parkinson’s, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and other neurological and psychiatric diseases.